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PAK proteins and YAP-1 signalling downstream of
integrin beta-1 in myofibroblasts promote liver
fibrosis
Katherine Martin1,2,*, James Pritchett1,2,*, Jessica Llewellyn1, Aoibheann F. Mullan1, Varinder S. Athwal1,2,
Ross Dobie3, Emma Harvey1, Leo Zeef4, Stuart Farrow1,5, Charles Streuli6, Neil C. Henderson3,
Scott L. Friedman7, Neil A. Hanley1,2 & Karen Piper Hanley1,2
Fibrosis due to extracellular matrix (ECM) secretion from myofibroblasts complicates many
chronic liver diseases causing scarring and organ failure. Integrin-dependent interaction with
scar ECM promotes pro-fibrotic features. However, the pathological intracellular mechanism
in liver myofibroblasts is not completely understood, and further insight could enable
therapeutic efforts to reverse fibrosis. Here, we show that integrin beta-1, capable of binding
integrin alpha-11, regulates the pro-fibrotic phenotype of myofibroblasts. Integrin beta-1
expression is upregulated in pro-fibrotic myofibroblasts in vivo and is required in vitro for
production of fibrotic ECM components, myofibroblast proliferation, migration and contrac-
tion. Serine/threonine-protein kinase proteins, also known as P21-activated kinase (PAK),
and the mechanosensitive factor, Yes-associated protein 1 (YAP-1) are core mediators of
pro-fibrotic integrin beta-1 signalling, with YAP-1 capable of perpetuating integrin beta-1
expression. Pharmacological inhibition of either pathway in vivo attenuates liver fibrosis. PAK
protein inhibition, in particular, markedly inactivates the pro-fibrotic myofibroblast phenotype,
limits scarring from different hepatic insults and represents a new tractable therapeutic target
for treating liver fibrosis.
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L
iver fibrosis is a common step in the majority of chronic
liver diseases and is increasing in incidence with a global
prevalence of 2% in the general population1,2. Although
potentially reversible during early stages, persistent injury and
scar formation results in end-stage cirrhosis, ultimately requiring
transplant. In cases in which the underlying cause of hepatic
injury cannot be determined and removed, treatment is limited
to addressing complications such as portal hypertension,
progression to hepatocellular carcinoma and liver failure3–5.
This problem makes anti-fibrotic liver therapy an urgent priority,
but no drugs have been approved to date6,7.
Hepatic stellate cells (HSCs; liver-specific pericytes) are
thought to be a major source of liver myofibroblasts8,9. In
response to injury, quiescent HSCs activate into proliferative,
migratory myofibroblasts. Although in vitro models of liver
fibrosis are an imperfect replica of disease in vivo, extraction and
culture of HSCs on plastic induces production of collagen-rich
extracellular matrix (ECM) characteristic of fibrosis, in part due
to the appearance and function of the transcription factor SOX9
(refs 10,11). It is this pathological ECM that causes contracted
scarring and increased organ stiffness.
Although poorly understood, the self-propagating cycle of
extracellular stiffness increasing intracellular contractile force is
thought to perpetuate fibrotic collagen deposition12. Conversely,
breaking this relationship could facilitate reversal of liver fibrosis.
In other settings, cellular sensing of increased matrix stiffness
leads to nuclear activation of the mechanosensitive trans-
criptional regulator Yes-associated protein 1 (YAP-1)13.
Interestingly, YAP-1 is expressed in activated HSCs and its
inhibition improves scarring in a rodent model of liver fibrosis14.
Thus, it is important to address directly in liver how ECM might
signal from the cell surface to factors in the nucleus, such as
YAP-1, as interfering with these pathways might arrest the
pro-fibrotic myofibroblast phenotype.
Cells contact the ECM at focal adhesions via cell-surface
integrin receptors, heterodimers composed of an alpha and beta
subunit15. Integrin function is important in HSCs16,17. In
particular, loss of integrin alpha-V in mice or agents that block
its function in rats protects against liver fibrosis18. However,
integrin alpha-V activates the pro-fibrotic cytokine transforming
growth factor-b (TGF-b) at the cell surface rather than signalling
directly to intracellular mechanosensing pathways18. A role for
the integrin beta-1 subunit has been proposed but not tested. In
skin, TGF-b-dependent mechanisms regulating integrin beta-1
have a major role in fibroblast function during fibrosis and
wound healing19. Thus, we hypothesize that defining intracellular
integrin beta-1 signalling in liver myofibroblasts might identify
pathways that mediate mechanotransduction and collagen
deposition in fibrosis. Through transcriptomic and experimental
analyses of integrin beta-1-deleted and wild-type myofibroblasts,
hierarchical clustering identifies mechanosensing pathways
involving PAK-1 and YAP-1 as core mediators of pro-fibrotic
integrin signalling. Pharmacological inhibition of either pathway
lessens the pro-fibrotic myofibroblast phenotype in vitro and
attenuates liver fibrosis in vivo. These data implicate PAK protein
inhibitors as particularly tractable for repositioning from clinical
trials in cancer as new anti-fibrotic agents, avoiding the need
to target integrin-ECM interactions, which are ubiquitous
throughout healthy and diseased tissue.
Results
Integrin beta-1 is required for pro-fibrotic HSCs. HSCs
extracted from the liver and cultured on plastic for 7–10 days
model myofibroblast activation with the appearance of a-Smooth
muscle actin (a-SMA), Sex determining region Y-box 9 (SOX9)
and the major fibrotic ECM protein, Collagen type 1 (COL1)
(refs 10,11,20). Itgb1 increased in parallel with these markers
(Fig. 1a,b and Supplementary Fig. 1a,b). Interestingly, while
integrin alpha-V was increased consistent with previous find-
ings18, ITGA11 was more strikingly enhanced following
activation of myofibroblasts when it co-precipitated with
integrin beta-1 (Supplementary Fig. 1c–e). To probe the
consequences of this integrin signalling, we isolated HSCs from
Itgb1fl/fl; CreERTM mice and treated the cells with tamoxifen to
inactivate Itgb1 or dimethyl sulfoxide (DMSO) as control21.
Following culture on plastic, activated HSCs lacking integrin
beta-1 had a 50–70% reduction in fibrotic markers a-SMA, COL1
and SOX9 (Fig. 1c–e). Stress fibres (marked by F-actin) were
greatly reduced and the myofibroblast-like appearance was lost in
the mutant HSCs which had a rounded phenotype and were less
than half as proliferative as control myofibroblasts (Fig. 1f–g and
Supplementary Fig. 1f). Loss of integrin beta-1 did not affect cell
viability or, in contrast to previous data22, apoptosis
(Supplementary Fig. 1g,h). Over 24 h single tracked integrin
beta-1-deficient myofibroblasts were markedly less migratory
than control cells (Fig. 1h,j). We also examined the consequences
of inactivating integrin signalling in myofibroblasts that had
already developed a pro-fibrotic phenotype; Itga11 knockdown or
later recombination of the Itgb1 allele diminished SOX9 and
COL1 levels (Supplementary Fig. 2a–c), and also drastically
reduced HSC migration (Supplementary Fig. 2d–f). Loss of
integrin beta-1 signalling in prior activated HSCs also disabled
collagen gel contraction independent of cell proliferation
(Fig. 1k,l). Collectively, these data demonstrate that abrogation
of integrin beta-1 signalling, potentially as ITGA11B1
heterodimers, both blocks and reverses major pro-fibrotic
features of liver myofibroblasts in vitro, including key markers,
cell migration, proliferation, contractility and collagen
production.
Downstream pathways of integrin beta-1 in activated HSCs.
These findings made it logical to explore the intracellular events
of integrin beta-1 signalling in hepatic myofibroblasts. We
analysed the transcriptome of integrin beta-1-deleted and wild-
type myofibroblasts, cultured on plastic for 7 days, versus their
freshly isolated quiescent HSC counterparts. Following hier-
archical analysis of replicate samples, displayed by heatmap,
differentially expressed genes clustered into seven categories
(Fig. 2a and microarray data set E-MTAB-4810). Loss of integrin
beta-1 did not convert activated myofibroblasts back to a quies-
cent phenotype, but a largely intermediate state consistent with
recent data on a separate population of inactivated HSCs that
arise during the resolution of murine liver fibrosis4. The two
largest clusters contained: 225 genes upregulated in activated
myofibroblasts whose expression was diminished without integrin
beta-1 signalling (Cluster 3); and the converse, 245 genes
downregulated in activated myofibroblasts whose expression
was partially restored without integrin beta-1 signalling (Cluster
7). Consistent with our phenotypic and functional data, Cluster 3
overrepresented genes involved in organizing contractility, ECM
signalling and the cytoskeleton (Fig. 2b,c and Supplementary
Fig. 3) whereas Cluster 7 genes included categorization as
inflammation, cell proliferation, adhesion and migration, and
wounding (Supplementary Fig. 4). Cluster 2 contained 73 genes
which became upregulated in inactivated myofibroblasts to levels
beyond those in quiescent HSCs and was also annotated by
wound healing and the regulation of cell proliferation
(Supplementary Fig. 5).
We reasoned that further analysis of Cluster 3 might prioritize
mechanosensing pathways which could be inhibited bene-
ficially to reduce collagen deposition in liver fibrosis. In the top
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20 gene-ontology terms most significantly associated with
Cluster 3 (Supplementary Fig. 6), Group I PAKs, for which there
are three family members, and myosin light chain 9 (MYL9), the
contractility protein, stood out as annotated 13 times. Interest-
ingly, during cell transformation PAK proteins can signal via the
mechanosensitive transcriptional coactivator, YAP-1 (ref. 23);
while in cancer-associated fibroblasts, YAP-1 can mediate the
effect of matrix stiffness on enhancing MYL9 production24.
Although PAK proteins and YAP-1 have been detected in
HSCs25,26, PAK, YAP-1 and MYL9 have not previously been
reported in integrin beta-1 signalling or collectively as regulators
of HSC function/liver fibrosis and therefore we set about
investigating these factors in greater detail.
Myocontractile HSCs require integrin beta-1 and YAP-1. YAP-1
and MYL9 were markedly increased following activation of wild-
type, but not integrin beta-1-deficient liver myofibroblasts (Fig. 3a–
e). Similarly, MYL9 and YAP-1 transcripts and protein were
diminished following abrogation of Itga11 (Fig. 3f,g and
Supplementary Fig. 8). Phosphorylation of YAP-1 blocks its
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Figure 1 | Integrin beta-1 is increased in activated HSCs and required for phenotype and function. (a) integrin beta-1 is increased in activated (A)
compared with quiescent (Q) rat HSCs by qRT–PCR. (b) Immunofluorescence of rat AHSCs shows integrin beta-1 costained in cells with pro-fibrotic
markers a-SMA (green; DAPI as blue nuclear counterstain) and SOX9 (red). (c,d) Activated mouse HSCs (‘Control’) show decreased protein levels for a-
SMA, COL1 and SOX9 by immunoblotting following the loss of integrin beta-1 (‘Itgb1-null’). Quantification from nZ3 experiments in c and example
immunoblots shown in d. (e) a-SMA is lost by immunofluorescence from activated mouse HSCs (‘Control’) following integrin beta-1 inactivation (‘Itgb1-
null’). DAPI (blue) used as nuclear counterstain. (f,g) Proliferation measured by BrdU incorporation of activated mouse HSCs (‘Control’) declines following
integrin beta-1 inactivation (‘Itgb1-null’). Quantification from nZ3 experiments in f with example immunofluorescence in g. DAPI, blue nuclear counterstain.
(h,j) Migration of activated mouse HSCs (‘Control’) over 24 h is almost entirely attenuated following the loss of integrin beta-1 (‘Itgb1-null’). Quantification
from n¼ 3 biological replicates with 30–77 cells in each experiment in h with an individual example of migratory tracks (in mm) shown in i,j. (k,l)
Contractile properties of activated mouse HSCs (‘Control’) are markedly attenuated after inactivation of integrin beta-1 (‘Itgb1-null’). Quantification of gel
contraction from n¼ 3 experiments is shown in k in the presence or absence of mitomycin-C (Mito-C) and example images shown in l. Scale bars, 50mm.
Two-tailed unpaired t-test was used for statistical analysis. Data are shown as means±s.e.m. *Po0.05, **Po0.01, zPo0.001. C, control-activated HSCs;
N, integrin beta-1-null HSCs.
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function by promoting nuclear export. Lack of integrin beta-1
caused nearly fourfold increase in phosphoYAP-1 and greater
cytoplasmic localization of total YAP-1 (Fig. 3h,i). YAP-1 functions
as a coactivator of the TEA domain family of transcription factors
(TEADs)27. We identified a conserved TEAD consensus motif in
the 30-untranslated region of MYL9 that was bound by a complex
that included YAP-1 and was required for YAP-1 induction of a
MYL9 reporter construct (Fig. 3j and Supplementary Fig. 7).
Verteporfin (VP) inhibits YAP-1 function by blocking its
interaction with TEAD27. Treating activated myofibroblasts with
VP reduced expression of Col1A1, Myl9 and Ctgf, a YAP-1 target
gene in fibroblasts and cancer cell lines28, and an indicator of HSC
activation29,30 (Fig. 3k). Interestingly, functional YAP was also
required for full Itga11 and Itgb1 expression implying an auto-
regulatory loop to perpetuate the pro-fibrotic myofibroblast
phenotype. Collectively, these data indicate that integrin beta-1,
potentially in partnership with ITGA11, signals via YAP-TEAD to
regulate the myocontractility factor, MYL9, in activated hepatic
myofibroblasts. To explore whether blocking YAP-1 function might
ameliorate liver fibrosis, we administered VP to mice in two
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different models of liver fibrosis. To model parenchymal hepatic
injury we induced fibrosis for 6 weeks using carbon tetrachloride
(CCl4) injections while treating with VP during the last 3 weeks. To
model peribiliary sclerosing disorders, fibrosis was induced for 2
weeks using bile duct ligation (BDL) with VP treatment during the
last week. In neither model was VP toxic to hepatocytes as assessed
by serum alanine aminotransferase (ALT) levels in control animals
(Supplementary Figs 9a and 10a). However, while VP restored ALT
and bilirubin to background levels only in the BDL model
(Supplementary Fig. 10a), fibrotic collagen deposition, assessed by
picro sirius red (PSR) staining, was significantly reduced in both
injury settings (Fig. 4a–d) consistent with trends post-treatment in
hydroxyproline content (Supplementary Figs 9b and 10b). While
VP did not alter myofibroblast numbers or inflammation in the
CCl4 model of parenchymal liver damage, both showed trends to
amelioration post-BDL (Supplementary Fig. 10e–h).
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NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12502 ARTICLE
NATURE COMMUNICATIONS | 7:12502 |DOI: 10.1038/ncomms12502 | www.nature.com/naturecommunications 5
PAK proteins contribute to pro-fibrotic myofibroblasts. There
are three group I PAK members (PAK-1, PAK-2 and PAK-3). In
contrast to PAK-2, PAK-1 and PAK-3 were both increased on
myofibroblast activation (Fig. 5a), however, this induction was
significantly reduced in the absence of integrin beta-1 (Fig. 5b) and
following abrogation of Itga11 (Fig. 5c and Supplementary Fig. 8).
Abrogating Pak1 or Pak3 using siRNAs in myofibroblasts with
intact integrin signalling reduced SOX9 and COL1 (Fig. 5d–e and
Supplementary Fig. 11). PAK can phosphorylate MYL proteins31.
Although we could not detect any alterations in total MYL9 levels,
its activated phosphorylated form, phosphoMYL9, was also
significantly decreased when Pak1 was knocked down (Fig. 5d,e).
The catalytic activity of PAK-1 and PAK-3 can be inhibited
allosterically by 1,1’-dithiodi-2-naphthol (IPA3) (ref. 32). Treating
activated rat and human hepatic myofibroblasts with IPA3
significantly reduced COL1 and SOX9 levels and blocked actin
filament formation resulting in a rounded cell phenotype very
similar to Itgb1-null HSCs (Fig. 5f,g and Supplementary Fig. 1f).
IPA3 treatment did not affect cell viability or further reduce fibrotic
markers in Itgb1-null activated HSCs, implying the effects of IPA3
were mediated by the same pathway as integrin beta-1
(Supplementary Fig. 12). In contrast to VP treatment, IPA3 also
increased expression of several markers of inactivated HSCs4,5,
while both VP and IPA3 reduced Col1a1 expression (Fig. 5h).
Inhibition of PAK-1 improves liver fibrosis in vivo. To inves-
tigate whether blocking PAK-1 function might improve liver
fibrosis, we administered IPA3 intraperitoneally to mice during
the last four weeks of an 8-week regime of CCl4 injections. IPA3
significantly reduced fibrotic collagen deposition in the hepatic
parenchyma by PSR staining while liver weight was unaffected
(Fig. 6a,b and Supplementary Fig. 13a). Liver hydroxyproline
content was also markedly reduced (Supplementary Fig. 13e). In
addition, in BDL-induced liver fibrosis the marked peribiliary
collagen deposition in control animals was greatly improved in
those animals that had been treated with three injections of IPA3
during the second week (Fig. 6c,d). Liver weight was unaltered
(Supplementary Fig. 13b). In both models, IPA3 also reduced the
amount of a-SMA staining in the liver implying reduced myofi-
broblast activation (Fig. 6e,f) consistent with the increased
expression of markers for HSC inactivation4,5 (Fig. 5h). Although
no clear significant improvements in liver function were detected
in serum (assessed by ALT and bilirubin levels), IPA3 treatment
showed no evidence of liver toxicity.
Taken together, these data demonstrate integrin beta-1
upstream of YAP-1 and PAK protein signalling in HSCs
in vitro; the importance of all three to the pro-fibrotic phenotype
of HSCs in vitro; and that inhibiting YAP-1 and PAK protein
function in vivo ameliorates liver fibrosis. As a final corroborative
step we examined HSCs isolated from liver fibrosis in vivo. We
followed an established protocol33,34 for extracting and analysing
HSCs following a total of four intraperitoneal injections of CCl4
or olive oil control every 2 days. Consistent with all the preceding
data, Itgb1, a-Sma, Col1, Yap1 and Pak1 were all increased in
HSCs from the fibrotic liver (Fig. 7a). Moreover, in the livers of
platelet-derived growth factor receptor beta (Pdgfrb) knock-in
reporter mice (Pdgfrb-BAC-eGFP) (ref. 18) there was a greater
detection of integrin beta-1 on the surface of live HSCs following
6-week CCl4 induction of liver fibrosis (Fig. 7b,c).
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Discussion
Liver fibrosis ultimately ending in cirrhosis complicates many
chronic liver diseases and urgently needs new therapeutic entities.
Although integrin beta-1 has previously been intimated as
important in HSC function as a putative partner for integrin
alpha-V, difficulty with myofibroblast-specific integrin beta-1
inactivation still precludes its direct investigation in liver fibrosis
in vivo as described by others18. Consequently, in this study we
have provided in vitro evidence for ITGA11-integrin beta-1
heterodimers in liver myofibroblasts, where loss of either
heterodimer led to an inactivated HSC phenotype remarkably
similar to recent data on fibrosis resolution4,5. Compared with
genetic inactivation of integrin beta-1, reliance on in vitro
transient knockdown prevented study of ITGA11 in cell
contraction or migration. Future genetic inactivation of ITGA11
will facilitate these investigations along with in vivo analyses. Our
data also do not preclude important interactions between integrin
beta-1 and other ITGA subunits. Although Itga3 was increased in
activated myofibroblasts we could not detect an interaction with
integrin beta-1. Although relatively little is known about the
molecular mechanisms by which ITGA11B1 functions, studies in
fibroblasts from other lineages support our data by invoking
potential regulation via mechanical stress35,36.
Targeting integrin beta-1 allowed us to identify downstream
intracellular pathways involving YAP-1 and PAK proteins. In the
liver, YAP-1 has been identified as an important regulator of
organ size and regeneration37. More recently, studies have
indicated YAP-1 is required for HSC activation in vitro,
whereas in vivo, a single dose of the YAP-1 inhibitor VP
improved scarring in mice with 4 week CCl4-induced fibrosis14.
Although our data from both CCl4 and BDL models of fibrosis
are in broad agreement with this latter study, in our hands the
short acting nature of VP required multiple weekly doses to
improve fibrosis in rodents; a single injection had no effect.
Molecularly, while there was marked overlap, we did not find
evidence for a hierarchical relationship between PAK proteins
and YAP-1. Notably, YAP-1 signalling preserved expression of
both integrin beta-1 and ITGA11 implying auto-regulation
similarly to YAP-1’s function in cancer-associated fibroblasts,
where MYL9 was a key regulator of the ECM and tumour
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Figure 5 | Integrin beta-1 inactivation identifies PAK signalling as a requirement for liver fibrosis. (a–f) Quantification of immunoblots showing: (a)
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invasion24. Interestingly, PAK-1 and PAK-2 appear to play
opposing roles in models of breast cancer. Inactivation of
PAK-2 enhanced phosphorylation of MYL and cell inva-
siveness, whereas PAK-1 inactivation had the opposite effect38.
These data are reminiscent of our own observations of quiescent
(PAK-2þ /PAK-1 and MYL9 ) versus activated HSCs
(PAK-2 /PAK-1þ and MYL9þ ). In keeping with these
opposing roles, studies have indicated PAK-2 negatively
regulates PAK-1 activity39. Because of a tendency for mice to
spontaneous recovery following CCl4 injections, it is difficult to
decipher agents that reverse liver fibrosis rather than attenuate or
inhibit its development. The in vitro data here all support reversal
of established pro-fibrotic myofibroblasts to a more inactivated
state. While additional signalling pathways might also influence
PAK-1 and YAP-1 in HSCs, in vivo, integrin beta-1 and PAK-1
(and YAP-1) were all co-increased in HSCs from fibrotic livers
and PAK protein inhibition clearly lessened fibrosis in two
different models of liver injury. While IPA3 is unsuitable for
clinical development, other Group I PAK inhibitors are already in
clinical trials for various cancers40. Moreover, drugs in current
clinical use exhibit PAK inhibitory activity and may be suitable
for therapeutic repositioning41,42. In summary, these data report
new mechanisms for liver fibrosis involving the group 1 PAK
proteins and YAP-1 as important effectors of integrin-dependent
signalling in hepatic myofibroblasts and highlight PAK inhibitors
as potential new agents with which to target liver fibrosis in
patients.
Methods
Animals. The Itgb1fl/fl and CreERTM mice have been described previously21. Adult
(8 weeks old) male mice were used and genotyping was performed from DNA
prepared from ear clips using the REDExtract-N-Amp Tissue PCR Kit (Sigma) and
PCR primers for integrin beta-1 forward 50-TTCTGCAAGTGTGGTG-30 and
reverse 50-TGCCACTCCAAACATAGAGC-30 and for b-actin CreER forward
50-AACCTGGATAGTGAAACAGGGGC-30 and reverse 50-GGAACCGACTT
GACGTAGCCAGC-30. Male Sprague–Dawley rats for HSC isolation were
purchased from Charles River Laboratories, UK. Pdgfrb-BAC-eGFP mice
(provided by Professor Neil Henderson, University of Edinburgh, UK) on a
C57BL/6 background carrying one copy of a BAC transgene expressing enhanced
green-green fluorescent protein (eGFP) under the control of Pdgfrb regulatory
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elements have been described previously18. Animals were housed and maintained,
and animal experiments performed under approval from the University of
Manchester Ethical Review Committee and UK Government Home Office licence
for animal research.
HSCs, gene silencing, recombination and compound treatment. Under term-
inal anaesthesia, primary HSCs were isolated by perfusing pronase and collagenase
through the liver via the portal vein, followed by isolation using Optiprep density
gradients (Axis-Shield Diagnostics Ltd). For mouse, HSCs from two to five livers
were combined per experimental replicate. For rat, sufficient HSCs were gained
from single animals per experimental replicate. For primary human HSCs (isolated
in the Liver Diseases Laboratory, Mount Sinai School of Medicine, NY, USA), in
lieu of perfusion, liver tissue was finely dissected and incubated for 40min at 37 C
in digestion buffer (0.5mgml 1 collagenase B, 0.2mgml 1 pronase)43. This was
followed by isolation using Optiprep density gradients (Axis-Shield Diagnostics
Ltd). Unless otherwise stated routine activation of primary HSCs was for
7 days by culture on tissue culture plastic with standard characterization for
expected changes in phenotype and gene expression as an internal control11.
Human LX2 cells were a gift from Professor Scott Friedman (Mount Sinai School
of Medicine) 44.
All cells were cultured in monolayer at 5% CO2 and 37 C in Dulbecco’s
modified Eagle’s mediumþ L-glutamine, Na-pyruvate and antibiotics
supplemented with fetal bovine serum; 10% for LX2 cells, or 16% for rat and
mouse HSCs. Gene silencing in HSCs was carried out transiently using 10 nmol
siRNA (Qiagen Supplementary Table 1 and for ITGA11 siRNA2: SMARTpool
ON-TARGETplus Itga11 siRNA, Dharmacon/GE Healthcare) or scrambled control
(Qiagen, UK) in Basic Nucleofector Kit T using programme U-25 on an Amaxa
Nucleofector (Lonza).
For genetic recombination of integrin beta-1, HSCs isolated from Itgb1fl/fl
CreERTM±mice were treated with 100 nM tamoxifen (or the equivalent volume of
ethanol vehicle for control) at the time of plating (day 0) and at media exchange on
day 1 until day 5 (when media was next changed). For the disruption of
YAP:TEAD complexes, 10mM VP (Sigma, UK) or the equivalent volume DMSO
vehicle control was included throughout media exchanges until cell collection.
To investigate PAK signalling in vitro, 15 mM IPA3 (Tocris Bioscience) or the
equivalent volume of DMSO vehicle control was added to the culture medium
of activated HSCs on day 7 for a further 24 h before collecting for downstream
analyses.
Microarray analysis. In two replicate experiments RNA was isolated using the
RNeasy kit (Qiagen) from HSCs extracted from Itgb1fl/fl CreERþ mice: on the day
of extraction (quiescent HSCs); or on day 8 (tamoxifen-treated ‘Itgb1-null’ or
control-activated HSCs). The efficiency of integrin beta-1 recombination in
tamoxifen-treated HSCs was 70–80% by qPCR (data not shown). RNA quality was
assessed by Agilent Bioanalyser. Labelled RNA was hybridized to the Affymetrix
Mouse Genome 430 2.0 Array platform according to Affymetrix protocols.
Background correction, quantile normalization and quantification of gene
expression were performed using RMA and differential expression was done with
limma in Bioconductor (PMID: 15461798). For cluster analysis, differential gene
expression was filtered by P valueo0.05 and fold change4±1.5 in the ‘Itgb1-null’
versus control-activated HSC groups. In all, 915 genes organised into 7 clusters
using a k-means clustering algorithm (maxdView software (http://bioinf.man.
ac.uk/microarray/maxd/); Fig. 2a and Supplementary Fig. S1). Clusters were
analysed using Database for Annotation, Visualisation and Integrated Discovery
(DAVID) version 6.7. Functional annotation clustering was carried out with
medium stringency; functional clusters with an enrichment score42 were selected,
and proportionately represented by enrichment scores. Analysis of clusters 5 and 6
did not reveal any functional annotation clusters with an enrichment score42.
Clusters of interest were examined by Ingenuity Pathway Analysis (Ingenuity
Systems, www.ingenuity.com).
Histology, immunohistochemistry and immunocytochemistry. Tissue samples
for histology and immunohistochemistry were fixed in 4% paraformaldehyde,
embedded in paraffin wax and sectioned at 5 mm thickness. All livers were
embedded in an identical orientation. Corresponding histology images within the
manuscript are shown from the same liver lobe. To detect a-SMA, immunohis-
tochemistry was carried out using anti a-SMA (M0851, DAKO, dilution: 1:100),
the Mouse on Mouse basic detection kit (Vector laboratories) and Vectorstain Elite
Avidin Biotin Complex (ABC) system (Vector laboratories). Antibody-complex
colour reactions were developed with diaminobenzidine and counterstained with
toluidine blue. The extent of scarring was assessed in livers using PSR staining
(Sigma). Quantification of PSR and a-SMA staining was determined by morpho-
metric analysis. Images were acquired from stained slide sections using the 3D
Histech Pannoramic 250 Flash II slide scanner. Ten regions which included all
three lobes of the liver (100 total magnification), were selected at random and
analysed using Adobe Photoshop. The Colour Range tool was used to select stained
pixels (red for PSR and brown for a-SMA); the number of selected pixels was
recorded and expressed as a fraction of the total number of pixels, averaged across
the 10 different regions per section. All quantification was carried out blinded,
without prior knowledge of sections or treatment/control group. For
immunocytochemistry, cells were cultured on glass chamber slides, fixed in 4%
paraformaldehyde and incubated with the following primary antibodies: anti-
integrin beta-1 (MAB1997, Millipore, dilution: 1:200), anti a-SMA (SMA-R-7-CE,
Leica Biosystems, dilution: 1:100), anti-SOX9 (AB5535, Millipore, dilution:
1:1,000), anti-YAP (Sc-101199, Santa Cruz, dilution: 1:200) and anti-PMYL9 (3671,
Cell Signalling, dilution: 1:50). For all immunofluorescence secondary antibodies
were 488 or 594 Alexa Fluors (Molecular Probes, Invitrogen) raised against the
appropriate species (dilution: 1:1,000). For G- and F-actin, cells were fixed in 3.7%
paraformaldehyde, permeabilized in 0.1% Triton X-100 in phosphate-buffered
saline (PBS) and incubated with Alexa Fluor 594 DNase I to detect G-actin
(Life Technologies) followed by Alexa Fluor 488 Phalloidin to detect F-actin
(Life Technologies).
Gene protein and co-immunoprecipitation analysis. For quantitative reverse-
transcription–polymerase chain reaction (qRT–PCR), RNA was extracted from
tissue and cells using RNeasy (Qiagen) and converted to cDNA using a High-
Capacity RNA-to-cDNA kit (Life Technologies). Intron-spanning primers were
used wherever possible (Supplementary Table 2). GusB and ActinB were used in
combination as standardizing ‘housekeeping’ genes for SYBR Green (Primer
Design, UK) gene expression assays. For in vivo activated HSCs Pdgfrb was used as
the reference gene, as recommended by Mederacke et al.34. Changes in mRNA
expression were calculated using DDCT methodology. Western blotting was carried
out using standard techniques and protein detected using the following primary
and secondary antibodies: anti-integrin beta-1 (MAB1997, Millipore, dilution:
1:1,000), anti-a-SMA (SMA-R-7-CE, Leica Biosystems, dilution: 1:100), anti-COL1
(1310-01, Southern Biotech, dilution:1:1,000), anti-SOX9 (AB5535, Millipore,
dilution: 1:5,000), anti-MYL9 (3672, Cell Signalling, dilution: 1:500), anti-YAP
(Sc-271134, Santa Cruz, dilution: 1:1,000), anti-PMYL9 (#3671P, Cell Signalling,
1:500), anti-PAK-1 (#2602, Cell Signalling, dilution: 1:1,000), anti-PAK-2
(#2604, Cell Signalling, dilution: 1:1,000), anti-PAK-3 (#2609, Cell Signalling,
dilution: 1:1,000), anti-ITGA11 (MAB4235, R&D Systems, dilution: 1:500),
anti-integrin alpha-V (611012, BD Transduction Laboratories, dilution: 1:500),
anti-Caspase (#9662S, Cell Signalling, dilution: 1:1,000), anti-b-actin horseradish
peroxidase conjugate (A3854, Sigma, dilution: 1:50,000) and species-specific
horseradish peroxidase conjugated secondary antibodies (GE Healthcare). For
immunoprecipitation of endogenous protein complexes, activated rat HSCs were
lyzed in NETN buffer (100mM NaCl, 20mM Tris-Cl, 0.5mM EDTA, 0.5% (v/v)
Nonidet P-40, 1EDTA free Protease Inhibitors, and 1 Inhibitor Cocktails 1
and 2). Cell lysate was pre-cleared with magnetic protein-G-coated beads (New
England Biolabs) and rat IgG (purified rat IgG, R&D Systems) to avoid non-
specific protein binding during the immunoprecipitation. To immunoprecipitate
integrin beta-1 protein complexes, magnetic protein-G beads were coated with
anti-integrin beta-1 (Millipore) or control IgG antibody (R&D Systems) and
incubated with cell lysate. Integrin beta-1 protein complexes were eluted from
beads by magnetic separation. Total supernatant and immunoprecipitated lysates
were analysed by immunoblotting using anti-integrin beta-1 (Millipore), anti-
ITGA11 (R&D Systems) and ITGA3 (AB1920, Millipore; data not shown).
Full-length uncropped blots are provided in Supplementary Fig. 14.
Chromatin immunoprecipitation. For chromatin immunoprecipitation, HSCs
were fixed in 1% formaldehyde for 10min, and chromatin prepared and sheared by
sonication to generate 200–1,000 bp fragments. Sheared chromatin was incubated
overnight at 4 C with 3 mg of anti-YAP (Sc-271134 X, Santa Cruz) or control IgG
antibody (R&D Systems) and magnetic protein-G-coated beads (pre-cleared with
sheared salmon sperm and BSA). Antibody-bead complexes were washed three
times in each of the following buffers: Buffer 1 (20mM Tris-HCl pH 8.1, 2mM
EDTA, 50mM EDTA, 0.1% SDS, 1% Triton X-100), Buffer 2 (10mM Tris-HCl pH
8.1, 1mM EDTA, 250mM LiCl, 1% NP-40, 1% Deoxycholate), and TE Buffer
(10mM Tris-HCl pH 8.1, 1mM EDTA). Protein-DNA complexes were eluted,
crosslinks reversed and DNA purified using MinElute columns (Qiagen). DNA was
analysed by PCR (Supplementary Table 2).
Cell migration. Activated HSCs were cultured in 24-well plates at a density of
5,000 cells per well. Single-cell tracks were acquired using live-cell imaging at
10min intervals over a 24 h period (AS MDW live cell imaging system, Leica).
Multiple position imaging was gathered using Image Pro 6.3 (Media Cybernetics
Ltd) and a Coolsnap HQ (Photometrics) camera with a Z optical spacing of 0.2 mm.
Cell movement over the 24 h period was analysed using ImageJ software with the
MTrackJ plug-in. Total length of the cell track (in mm) was generated for multiple
cells (details are provided in the figure legends), averaged and normalized to
control. Where individual cell migration tracks are shown, the co-ordinates at
10min intervals were plotted relative to each cell’s starting point (set at 0,0).
Cell proliferation. Cell proliferation was assessed using BrdU incorporation.
Activated HSCs were plated onto chamber slides (5,000 cells per well) and incu-
bated with 30mM BrdU (Sigma, UK) for 4 h. Cells were fixed and processed for
immunofluorescence counterstained with DAPI. BrdU was detected using sheep
anti-BrdU primary antibody (ab1893; Abcam, UK, 1:1,000) and donkey anti-sheep
fluorescein isothiocyanate (FITC)-conjugated secondary antibody (Abcam, 1:500).
Images were captured from two areas of each chamber well at  100 total
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magnification (Axio AI Imager and Axiovision software). BrdUþ /DAPIþ nuclei
were counted using Adobe Photoshop CS4 software and expressed as a percentage
of the total DAPIþ population.
Collagen gel contraction assay. Because of the large quantity of cells required for
a type I collagen gel contraction assay, Itgb1fl/fl CreERþHSCs were activated in
culture for 7 days before incubation with 100 nM tamoxifen (‘Itgb1-null’) or
ethanol vehicle (‘Control’) for a further 48 h. Inactivation of integrin beta-1 was
confirmed as described earlier (in addition to which extra cell migration assays
were performed (Supplementary Fig. S2)). The collagen gel contraction assay was
performed based on a previous protocol19. A total of 75,000 control or ‘Itgb1-null’
HSCs were suspended in culture medium mixed with type I collagen, and aliquoted
into a 12-well culture plate. Once polymerised, gels were detached from the sides of
the well, imaged (time zero; Biorad Chemidoc under white light), and re-imaged
after 24 h free-floating culture at 37 C. Gel contraction was calculated using
ImageJ software as the change in gel surface area between time zero and 24 h.
Results are expressed as a percentage of the contraction achieved by control-
activated HSCs.
Cell viability. Cell viability was assed using the 3-(4-5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) assay (Sigma) as per the manufacturer’s
instructions. A total of 25,000 activated HSCs, assessed to be growing in log phase,
were plated per well of a 6-well plate. Cell viability was detected at 560 nm
absorbance in the presence of MTT solvent.
Plasmids and luciferase assay. Full-length human YAP1 cDNA was sub-cloned
from a pcDNA Flag-YAP1 vector (plasmid 18881, Addgene, Cambridge, USA)45
into the KpnI(5’)/XbaI(3’) sites of pcDNA3.1zeoþ (Life Technologies) using
forward (50-CCCGGTACCATGGATCCCGGGCAGCAGCCG-30 and reverse
50-TCGTCTAGACTATAACCATGTAAGAAAGCT-30) primers. The sequence
containing the TEAD-binding site of human MYL9 gene was cloned into KpnI/
XhoI sites of the pGL3-promoter reporter vector (Promega, UK) from human
genomic DNA using forward (50-AGTGGTACCGTCCCAGTTCCC-30) and
reverse 50-CATGCTCGAGCATTTGTGTGGGGATAC-30) primers. The mutated
MYL9 pGL3-promoter vector was generated by deleting the 50-CATTCC-30
conserved TEAD-binding motif. LX2 cells were transfected with the reporter
plasmids plus pRL-TK (Promega) and the YAP expression vector or control empty
vector using Transfast reagent (Promega). Luciferase activity in cell lysates was
detected using the Dual-Luciferase reporter assay system (Promega). Relative
reporter units were normalized to Renilla luciferase activity from the pRL-TK
vector. All results are shown compared with the relevant empty vector controls.
CCl4-induced fibrosis. Mice were given intraperitoneal (i.p.) injections of 2 ml per
g body weight CCl4 (Sigma) at ratio of 1:3 by volume in olive oil (Sigma) or olive oil
alone (control) twice weekly for 8 weeks.
For the VP (VP) experiments, fibrosis was induced by CCl4 injections for 6
weeks with VP treatment for the final 3 weeks. VP was dissolved in 10% DMSO in
PBS to a concentration of 10mgml 1. Ten microlitre per g body weight (100mg
VP/kg bodyweight) was injected i.p. three times per week (on alternate days to
CCl4 or olive oil). Control mice were injected with DMSO. This created four
treatment groups: olive oilþDMSO (n¼ 5); olive oilþVP (n¼ 3); CCl4þDMSO
(n¼ 3); and CCl4þVP (n¼ 4).
Treatment with IPA3 (Tocris Bioscience) or DMSO (Sigma) occurred during
the final 4 weeks. IPA3 was dissolved in DMSO to a concentration of 4 mg ml 1;
1 ml per g body weight (4mg IPA3/kg bodyweight) was injected i.p. three times per
week (on alternate days to CCl4 or olive oil injections). Control mice were injected
with DMSO. This created four treatment groups: olive oilþDMSO (n¼ 5); olive
oilþ IPA3 (n¼ 5); CCl4þDMSO (n¼ 5); and CCl4þ IPA3 (n¼ 5).
BDL induction of fibrosis. Under anaesthesia the bile duct was exposed and
ligated using two ligatures. Sham-operated mice underwent the same procedure but
without tying the ligatures. BDL mice developed cholestasis and associated fibrosis
over a 14-day period.
As for CCl4, VP was dissolved in 10% DMSO in PBS to a concentration of
10mgml 1. 10ml per g body weight (100mg VP/kg bodyweight) and was injected
every 48 h starting on day 7 after BDL. This created four treatment groups:
shamþDMSO (n¼ 8), shamþVP (n¼ 4), BDLþDMSO (n¼ 7), BDLþVP
(n¼ 5).
For IPA3, at equal intervals during the second post-operative week, mice were
given three i.p. injections of 4 mgml 1 IPA3 (1 ml per g body weight) in DMSO, or
DMSO alone. This created four treatment groups: shamþDMSO (n¼ 4);
shamþ IPA3 (n¼ 4); BDLþDMSO (n¼ 8); and BDLþ IPA3 (n¼ 7).
At the end of all experiments, animals were killed, blood taken for liver function
biochemistry, liver and body weight recorded and livers processed for histology.
Isolation of in vivo activated HSCs. In vivo activated mouse HSCs were induced
and isolated exactly as described in the published study by De Minicis et al.33. In
brief, mice were injected i.p. on 4 occasions at 2-day intervals with 2 ml per g body
weight CCl4 (Sigma) at a ratio of 1:3 by volume in olive oil (Sigma) or olive oil
alone (control). HSCs were then isolated by liver perfusion and density gradient as
described above and prepared for qPCR analysis as described previously33,34. In
addition, in vivo activated GFP-labelled HSCs were also extracted from Pdgfrb-
BAC-eGFP reporter mice following 6-weeks CCl4-induced fibrosis or olive oil
control for analysis by fluorescence-activated cell sorting (FACS) as previously
described18. The GFP-positive cells were resuspended in FACS buffer (PBS
supplemented with 2% FCS and 2mM EDTA). Following a 10min block with 10%
mouse serum and CD16/32, cells were incubated with a phycoerythrin-conjugated
anti-integrin beta-1 (12-0291, 1:200) or isotype control (12-4888, 1:200; both from
eBioscience) at 4 C for 20min in the dark18. Cells were washed, resuspended in
FACS buffer and single, live, GFP-positive HSCs analysed on a Becton Dickinson
LSR Fortessa.
Hydroxyproline assay. Hydroxyproline content was measured using the Quick-
Zyme Biosciences Total Collagen Assay and Total Protein Assay kits (QuickZyme
Biosciences, The Netherlands). Liver tissue was hydrolysed from 10 10 mm thick
paraffin-embedded sections in HCl at 95 C for 20 h as per the manufacturer’s
instructions. Hydroxyproline content was determined by absorbance at 570 nm
against standard kit controls and expressed per total amount of protein assessed in
the sample.
Statistical analysis. Statistical significance was determined by two-tailed Student’s
t-test. All experiments were carried out three times or more (n¼ 3).
Data availability. Microarray data that support the findings of this study have
been deposited in ArrayExpress with the accession code E-MTAB-4810. The
authors declare that all other data supporting the findings of this study are available
within the article and its Supplementary Information files, or from the corre-
sponding author on request.
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